Member Info for Krone

RMM - interestingly Stephen Parker has just liked the Sierra tweet re the appointment of Ms Thompson.....cryptic clue perhaps?

Ghjones - thanks for clarifying.

Correction - assuming they are all buys and that some are delayed from last week?

Chocks away indeed!!!

Hi Stoney, one would have thought that Stephen Dilly, who received a $7m golden hello would want to be seen to be taking some decisive action to get SRA737 sorted!

Hi Thoth, Is there an obligation on the part of the BoD to issue an RNS, albeit belatedly, in respect of the published Chinese research Re 20347 that you identified quite some time ago?
https://biosignaling.biomedcentral.com/articles/10.1186/s12964-018-0251-0

Ghjones1 - many thanks for the very helpful explanation. All looking good for another exciting week ahead.

NUM4 - there was a change of emphasis re timescale noted between 3 June and 1 July, which may or may not be intentional.
3 June 2020: These new funds will be used to advance their preclinical studies targeting completion in at least one indication LATE THIS YEAR, pending successful progress.
1 July 2020: Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the “cytokine storm” immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). The Company is targeting COMPLETION OF PRECLINICAL DEVELOPMENT IN 2020.

And don’t forget JAKs in the context of Sepsis - a potentially massive market with limited current therapies!
https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(20)30158-1

Note 2 x late reported £22k buys this morning!!

Sareum Holdings plc, the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, presented data yesterday demonstrating how SDC-1802 (formerly known as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by Sareum, significantly reduces tumour growth in disease models of cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma. The studies showed that SDC-1802 induces this anti-cancer activity through a novel immunotherapeutic mechanism of action that stimulates the local immune system to attack cancer cells.

RMM - this should clarify http://www.sareum.com/files/5915/7192/3767/TYK2_Poster_EORTC_2019_v2.pdf

And Sepsis.....

Potential for 'an exciting new avenue of treatment'
Study leader Professor Chris Lord, Deputy Head of Breast Cancer Research at The Institute of Cancer Research, London, said:
“Cancers that have repaired their BRCA mutations are difficult to treat, as their cells have recovered some of the properties of normal cells – in many ways this means that there are no obvious vulnerabilities to target. But we often noted that the way in which some cancer cells repair BRCA genes means that the proteins that they make are not completely normal, and could be recognised by the immune system as foreign, opening up ways to target and treat these cancers by using the immune system.
“We could use immunotherapy drugs like checkpoint inhibitors to harness the body’s immune response, and direct it at reversion mutations. That has the potential to open up an exciting new avenue of treatment for patients with aggressive cancers that are resistant to the best available current drugs.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“Cancer evolution and drug resistance is the biggest challenge we face in research and treatment today. Studies like this are incredibly valuable in dissecting out how, why and when cancers can evolve resistance to current drugs.

“Excitingly, this research opens up the potential for a brand new approach to treatment that uses cancer’s defences against it, by targeting the very mutations which give the disease resistance to existing drug therapy.”

Dr Emily Armstrong, research information manager at Cancer Research UK, said:

"Genetic faults in the BRCA genes are involved in multiple cancers including breast and ovarian cancers, so tackling drug resistance associated with these genes could change the lives of a huge number of people.

"This is only a computational prediction at the moment, but it will be very exciting to test in the lab whether the immune system can indeed tell the difference between the healthy proteins and the rewired ones produced by cancer cells, and effectively turn the tumours’ resistance mechanism against them."

Further evidence, if further evidence is needed, to support Sareum's position.
"Considering the complexity of JAK-depending processes and their involvement in multiple disorders, JAK inhibitors are the perfect candidates fordrug repurposing and for the assessment of multitarget strategies".
https://doi.org/10.3390/molecules25153321 - Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates

Coincidental tweet?
https://twitter.com/investormeetco/status/1285998045553926144?s=21

RMM - many thanks for your considered and very helpful opinion.
Ultimately I guess the return will be somewhere between X and Y, where X is a large number and Y is a very large number!

https://endpts.com/gilead-lines-up-a-1-55b-biotech-buyout-deal-as-ceo-dan-oday-invests-in-his-latest-cancer-blockbuster-dream/

Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million
– Gilead to Acquire 49.9% Equity Interest in Tizona –

– Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments –

– Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –

Correction - don't we actually have 5 possibilities -
SDC1801 Covid,
SDC1801 autoimmune,
SDC1802 cancer,
FLT3 Aurora ?,
SRA737 cancer x ?